{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:22:43Z","timestamp":1771039363895,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T00:00:00Z","timestamp":1349654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ocular inflammatory reactions have been described in patients on bisphosphonate treatment. We estimated the incidence rate of ocular inflammation at 3 and 12 months in patients treated for osteoporosis using a register-based cohort linked to prescription data (hospitals and private practice) and hospital data. From January 1, 1997 to December 31, 2007, a total of 88,202 patients beginning osteoporosis therapy were identified. Of those patients, 82,404 (93%) began oral bisphosphonates and 5798 (7%) nonbisphosphonates. Within the first year of treatment, 4769 (5.4%) of patients on osteoporosis therapy filled one or more prescriptions for topical eye steroids (TES). TES treatment rates (per 1000 patient-years) in the first year of osteoporosis treatment were 44 (95% confidence interval [CI] 42 to 46) for alendronate, 40 (95% CI 38 to 43) for etidronate, 45 (95% CI 35 to 57) for risedronate, 32 (95% CI 27 to 37) for raloxifene, and 64 (95% CI 49 to 83) for strontium ranelate. After adjustment for age, Charlson index, and the number of comedications, pulmonary disease in men was associated with an increased use of TES (odds ratio [OR]\u2009=\u20091.48; 95% CI 1.17 to 1.86; p\u2009=\u20090.001). In women, malignant disease (OR\u2009=\u20091.27; 95% CI 1.02 to 1.60; p\u2009=\u20090.04) and pulmonary disease (OR\u2009=\u20091.32; 95% CI 1.07 to 1.62; p\u2009=\u20090.01) were significant predictors at 3 months and rheumatic diseases at 12 months (OR\u2009=\u20091.20; 95% CI 1.10 to 1.31; p\u2009&amp;lt;\u20090.001). There was no significant difference between the different drug classes (bisphosphonates versus nonbisphosphonates, alendronate versus nonalendronate-bisphosphonates) for risk of ocular inflammation, with age and the number of comedications being the only significant predictors. Hospital-treated uveitis (48 patients, or 0.05%) showed a similar trend. In conclusion, after initiation of treatment for osteoporosis, the risk of inflammatory eye reactions requiring TES is relatively low and not significantly different between bisphosphonate and nonbisphosphonate users. Patients with a rheumatic or pulmonary disease are at increased risk. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1783","type":"journal-article","created":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T18:37:19Z","timestamp":1349721439000},"page":"455-463","source":"Crossref","is-referenced-by-count":37,"title":["Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database"],"prefix":"10.1093","volume":"28","author":[{"given":"Michael","family":"Pazianas","sequence":"first","affiliation":[{"name":"Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma M","family":"Clark","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, Musculoskeletal Research Unit, University of Bristol, Bristol, United Kingdom, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia A","family":"Eiken","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nephrology and Endocrinology, Hiller\u00f8d Hospital, Hiller\u00f8d, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Brixen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology M, Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"Department of Medicine F, Gentofte Hospital, Hellerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,10,8]]},"reference":[{"key":"2024020318430014800_bib1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(93)93029-Z","article-title":"Bisphosphonates iritis","volume":"341","author":"Siris","year":"1993","journal-title":"Lancet."},{"issue":"3","key":"2024020318430014800_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1445-5994.1994.tb02186.x","article-title":"Uveitis associated with pamidronate","volume":"24","author":"Ghose","year":"1994","journal-title":"Aust NZ J Med."},{"key":"2024020318430014800_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(14)72902-2","article-title":"Pamidronate disodium and possible ocular adverse drug reactions","volume":"118","author":"Macarol","year":"1994","journal-title":"Am J Ophthalmol."},{"key":"2024020318430014800_bib4","first-page":"837","article-title":"Ocular inflammation associated with alendronate therapy","volume":"117","author":"Mbekeani","year":"1999","journal-title":"Arch Ophthalmol."},{"issue":"8","key":"2024020318430014800_bib5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/rheumatology\/40.8.956","article-title":"Idiopathic orbital inflammation following intravenous pamidronate","volume":"40","author":"Ryan","year":"2001","journal-title":"Rheumatology (Oxford)."},{"key":"2024020318430014800_bib6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bjo.86.12.1443","article-title":"Bilateral acute anterior uveitis after alendronate","volume":"86","author":"Malik","year":"2002","journal-title":"Br J Ophthalmol."},{"key":"2024020318430014800_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9394(02)01840-8","article-title":"Scleritis and other ocular side effects associated with pamidronate disodium","volume":"135","author":"Fraunfelder","year":"2003","journal-title":"Am J Ophthalmol."},{"key":"2024020318430014800_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ard.62.4.378","article-title":"Clodronate induced uveitis","volume":"62","author":"Fietta","year":"2003","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"2024020318430014800_bib9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archopht.121.9.1335","article-title":"Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer","volume":"121","author":"Subramanian","year":"2003","journal-title":"Arch Ophthalmol."},{"key":"2024020318430014800_bib10"},{"issue":"2","key":"2024020318430014800_bib11","first-page":"85","article-title":"Bisphosphonates and intraocular inflammation","volume":"79","author":"Asensio S\u00e1nchez","year":"2004","journal-title":"Arch Soc Esp Oftalmol."},{"key":"2024020318430014800_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.eye.6700542","article-title":"Diplopia following intravenous administration of pamidronate","volume":"18","author":"Meaney","year":"2004","journal-title":"Eye."},{"key":"2024020318430014800_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.eye.6701461","article-title":"Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy","volume":"19","author":"Durnian","year":"2005","journal-title":"Eye."},{"key":"2024020318430014800_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2407-5-156","article-title":"Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer","volume":"5","author":"El Saghir","year":"2005","journal-title":"BMC Cancer."},{"key":"2024020318430014800_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/01.SMJ.0000152753.80490.9F","article-title":"Bisphosphonate-associated scleritis a case report review","volume":"98","author":"Leung","year":"2005","journal-title":"South Med J."},{"key":"2024020318430014800_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3816\/CLM.2006.n.053","article-title":"Scleritis complicating zoledronic acid infusion","volume":"7","author":"Benderson","year":"2006","journal-title":"Clin Lymphoma Myeloma."},{"key":"2024020318430014800_bib17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/01.ico.0000225713.00630.e5","article-title":"Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy","volume":"25","author":"Richards","year":"2006","journal-title":"Cornea."},{"key":"2024020318430014800_bib18","first-page":"U1888","article-title":"Drug-induced optic neuritis uveitis secondary to bisphosphonates","volume":"119","author":"Stack","year":"2006","journal-title":"NZ Med J."},{"issue":"12","key":"2024020318430014800_bib19","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3899\/jrheum.080273","article-title":"Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer","volume":"35","author":"Banal","year":"2008","journal-title":"J Rheumatol."},{"issue":"2","key":"2024020318430014800_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12032-007-9006-2","article-title":"A case report: zoledronic acid-induced anterior uveitis","volume":"25","author":"Kilickap","year":"2008","journal-title":"Med Oncol."},{"key":"2024020318430014800_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5694\/j.1326-5377.2008.tb01658.x","article-title":"Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer","volume":"188","author":"Moore","year":"2008","journal-title":"Med J Aust."},{"issue":"1","key":"2024020318430014800_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archophthalmol.2007.17","article-title":"Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma","volume":"126","author":"Phillips","year":"2008","journal-title":"Arch Ophthalmol."},{"issue":"13","key":"2024020318430014800_bib23","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMc0803366","article-title":"Zoledronic acid infusion and orbital inflammatory disease","volume":"359","author":"Sharma","year":"2008","journal-title":"N Engl J Med."},{"key":"2024020318430014800_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/09273940902916111","article-title":"Anterior uveitis complicating zoledronic acid infusion","volume":"17","author":"Colucci","year":"2009","journal-title":"Ocul Immunol Inflamm."},{"issue":"3","key":"2024020318430014800_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000202646","article-title":"Bilateral uveitis secondary to bisphosphonate therapy","volume":"223","author":"Tan","year":"2009","journal-title":"Ophthalmologica."},{"issue":"10","key":"2024020318430014800_bib26","first-page":"1015","article-title":"Ocular side effects of bisphosphonates: a case report and literature review","volume":"56","author":"McKague","year":"2010","journal-title":"Can Fam Physician."},{"key":"2024020318430014800_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00198-009-1048-1","article-title":"Orbital inflammatory disease secondary to a single-dose administration of Zoledronic acid for treatment of postmenopausal osteoporosis","volume":"21","author":"Procianoy","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024020318430014800_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/WNO.0b013e3181c1a589","article-title":"Another case of bisphosphonate-induced orbital inflammation","volume":"30","author":"Yang","year":"2010","journal-title":"J Neuroophthalmol."},{"key":"2024020318430014800_bib29","author":"Fosamax\u00ae"},{"key":"2024020318430014800_bib30","author":"Actonel\u00ae"},{"key":"2024020318430014800_bib31","author":"Boniva\u00ae"},{"issue":"18","key":"2024020318430014800_bib32","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"issue":"18","key":"2024020318430014800_bib33","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"issue":"6","key":"2024020318430014800_bib34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IAE.0b013e31816576ef","article-title":"Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort","volume":"28","author":"French","year":"2008","journal-title":"Retina."},{"issue":"8","key":"2024020318430014800_bib35","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates a retrospective cohort study","volume":"184","author":"Etminan","year":"2012","journal-title":"CMAJ."},{"issue":"Suppl 1","key":"2024020318430014800_bib36","first-page":"93","article-title":"[Preclinical toxicology of bisphosphonates]","volume":"57","author":"Mondelo","year":"1997","journal-title":"Medicina (B Aires)."},{"issue":"2","key":"2024020318430014800_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0928-0987(98)00065-7","article-title":"Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite","volume":"8","author":"Makkonen","year":"1999","journal-title":"Eur J Pharm Sci."},{"key":"2024020318430014800_bib38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11926-996-0017-3","article-title":"Inflammatory conditions of the eye associated with rheumatic diseases","volume":"3","author":"Afshari","year":"2001","journal-title":"Curr Rheumatol Rep."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1783","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/3\/455\/56564234\/1783_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/3\/455\/56564234\/1783_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:48:00Z","timestamp":1710341280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/3\/455-463\/7598759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,8]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,10,8]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1783","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,3,1]]},"published":{"date-parts":[[2012,10,8]]}}}